Table 4.

HRs for type 2 diabetes in men with prostate cancer on GnRH agonists for different periods of exposure

Years of exposure	Number of events	Number of patients	HR	95% CI	aHR*	95% CI
ADT-free cohort	570	14 502	ref.	–	Ref.	–
0–1	369	6800	1.41	1.23 to 1.61	1.38	1.21 to 1.58
1–2	139	2177	1.60	1.33 to 1.93	1.59	1.32 to 1.92
2–3	105	1330	1.77	1.44 to 2.18	1.76	1.42 to 2.17
3–5	96	1151	1.74	1.40 to 2.16	1.73	1.42 to 2.17
>5	50	606	1.58	1.18 to 2.11	1.57	1.17 to 2.10

*Adjusted for age and stage.

ADT, androgen deprivation therapy; GnRH, gonadotropin-releasing hormone.